A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-15

Study Completion Date

2027-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years of age in China. This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China.

This study is seeking healthy participants of 6 groups:

* Group 1: Adults ≥18 to \<50 years of age
* Group 2: Children ≥2 to \<6 years of age
* Group 3: Children ≥12 months to \<2 years of age
* Group 4: Infants ≥7 to \<12 months of age
* Group 5: Infants ≥42 to ≤98 days of age
* Group 6: Infants ≥42 to ≤98 days of age

All participants in Group 1 to 5, in this study will receive 20vPnC as per the age-specific dosing schedules:

* Group 1: participants will receive 1 dose of 20vPnC.
* Group 2: participants will receive 1 dose of 20vPnC.
* Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1.
* Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to \<455 days of age and at least 56 days after Dose 2.
* Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age.

Participants in Group 6 will be randomized in a 1:1 ratio to received either 20vPnC or 13vPnC:

\- Group 6: participants will receive 4 doses of 20vPnC or 13vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age.

The study will look at the experiences of people receiving the study vaccine. The study will also look at the immune response of some people receiving the study vaccine. This will help decide if the study vaccine is safe.

The total duration of taking part in the study from each group is:

* Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits.
* Participants in Group 3 will take part for about 8 months, with 9 visits.
* Participants in Group 4 will take part for about 12 months, with 8 visits.
* Participants in Group 5 and 6 will take part for about 16 to 19 months, with 11 visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

NCT07019909

Pneumococcal Disease

ACTIVE_NOT_RECRUITING PHASE1

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

NCT01531322

Pneumococcal Infection

COMPLETED PHASE1

PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

NCT07025876

Streptococcus Pneumoniae Pneumonia

COMPLETED EARLY_PHASE1

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

NCT03574389

Pneumococcal Infections Pneumococcal Conjugate Vaccine

COMPLETED PHASE3

A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria

NCT01193582

Pneumococcal Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

This is an open label study. Participant, investigators, and sponsor will be unblinded to the participant's assigned study intervention.

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

20vPnC

20vPnC vaccine

Intervention Type BIOLOGICAL

13vPnC

13vPnC vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants:

* Adults ≥18 to \<50 years of age
* Children ≥2 to \<6 years of age
* Children ≥12 months to \<2 years of age
* Infants ≥7 to \<12 months of age
* Infants ≥42 to ≤98 days of age
* Healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study.

Exclusion Criteria

* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine.
* History of microbiologically proven invasive disease caused by S pneumoniae.
* Congenital, functional, or surgical asplenia.
* Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation.
* Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s).

Please refer to the study contact for further eligibility details.

Minimum Eligible Age

42 Days

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes